Clinical trial
A Phase 2 Clinical Trial to Assess the Safety and Efficacy of Complement 3 Inhibitor, AMY-101, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 (SAVE)
NCT04395456 is registered in ClinicalTrials.gov with Amyndas Pharmaceuticals S.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Clinical Trial to Assess the Safety and Efficacy of Complement 3 Inhibitor, AMY-101, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 (SAVE)
- Lead sponsor
- Amyndas Pharmaceuticals S.A.
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- September 30, 2021
- Completion date
- December 31, 2022
- Enrollment
- 144 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
acute respiratory distress syndrome due to sars-cov-2 infection (severe covid19)